Queen Mary has led the development of bone substitute materials which are now used in 100,000's of patients across the globe. Two spin out companies from Queen Mary, Progentix Orthobiology and ApaTech (acquired in 2010 by Baxter International) have commercialised research into these important biomaterials. In 2010, the bone substitute materials sold by ApaTech, had 4% of the US bone graft market, an annual revenue of £220 million. To date, ApaTech bone graft substitutes have treated over 370,000 patients in over 30 countries. Dr Karin Hing has recently been recorded for a short film explaining her pioneering research on development of bone graft substitutes at Queen Mary. In the video, Karin explains how synthetic bone graft materials are developed, how they are used and the importance they play in patients' lives.